David A. Siegel Igm Biosciences, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 82,700 shares of IGMS stock, worth $105,029. This represents 0.0% of its overall portfolio holdings.
Number of Shares
82,700
Previous 90,500
8.62%
Holding current value
$105,029
Previous $104,000
11.54%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding IGMS
# of Institutions
64Shares Held
15MCall Options Held
0Put Options Held
0-
Baker Bros. Advisors LP New York, NY4.1MShares$5.2 Million0.05% of portfolio
-
Siren, L.L.C. New York, NY3.26MShares$4.13 Million0.19% of portfolio
-
Redmile Group, LLC San Francisco, CA2.95MShares$3.75 Million0.4% of portfolio
-
Black Rock Inc. New York, NY883KShares$1.12 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY855KShares$1.09 Million0.0% of portfolio
About IGM Biosciences, Inc.
- Ticker IGMS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,969,000
- Market Cap $36.8M
- Description
- IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...